866-997-4948(US-Canada Toll Free)

Pol Polyprotein - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 53 Pages

Pol Polyprotein - Pipeline Review, H2 2016

Summary

Global Markets Directs, Pol Polyprotein - Pipeline Review, H2 2016, provides in depth analysis on Pol Polyprotein targeted pipeline therapeutics.

The report provides comprehensive information on the Pol Polyprotein, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Pol Polyprotein targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Pol Polyprotein
- The report reviews Pol Polyprotein targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Pol Polyprotein targeted therapeutics and enlists all their major and minor projects
- The report assesses Pol Polyprotein targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Pol Polyprotein targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Pol Polyprotein
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pol Polyprotein development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pol Polyprotein Overview 6
Therapeutics Development 7
Pol Polyprotein - Products under Development by Stage of Development 7
Pol Polyprotein - Products under Development by Therapy Area 8
Pol Polyprotein - Products under Development by Indication 9
Pol Polyprotein - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Pol Polyprotein - Products under Development by Companies 12
Pol Polyprotein - Products under Development by Universities/Institutes 14
Pol Polyprotein - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Pol Polyprotein - Companies Involved in Therapeutics Development 21
GeoVax Labs, Inc. 21
Inovio Pharmaceuticals, Inc. 22
Johnson & Johnson 23
Pol Polyprotein - Drug Profiles 24
GOVXB-11 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
GOVXC-11 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
GOVXC-21 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
HIV [serotype Ad26] (tetravalent) vaccine - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
HIV-1 (bivalent) vaccine - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
HIV-1 vaccine 11 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
HIV-1 vaccine 5 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
MVATG-17401 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
PENNVAX-B - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
PENNVAX-GP - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Pol Polyprotein - Dormant Projects 40
Pol Polyprotein - Featured News & Press Releases 41
Oct 20, 2016: GeoVax HIV Vaccine Clinical Data Presented at HIVR4P Conference 41
Aug 02, 2016: GeoVax Awarded NIH Contract for up to $7.8 Million to Manufacture HIV Vaccine for Advanced Human Clinical Trials 41
Jul 14, 2016: Inovio Deploys DNA-based Monoclonal Antibody Technology in Quest to Cure HIV 42
Jun 30, 2016: GeoVax Announces Filing of Investigational New Drug Application for HIV Human Clinical Trial 43
May 18, 2016: GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 43
Apr 14, 2016: GeoVax Awarded $1.4M NIH Grant 44
Mar 07, 2016: Strong Protection Elicited by an Immunodeficiency Virus Vaccine in Non-Human Primates 45
Sep 08, 2015: Inovio Pharmaceuticals Announces First Patient Dosed With Universal HIV Vaccine 45
Apr 14, 2015: GeoVax to Seek Dual Pathway for Advancing Its HIV Preventive Vaccine 46
Apr 09, 2015: GeoVax Provides Details of Presentation at World Vaccine Congress 47
Apr 01, 2015: GeoVax Provides Update on Its HIV Vaccine Program 48
Mar 16, 2015: Inovio Pharmaceuticals and Academic Collaborators Receive $16 Million HIV Grant From National Institute of Allergy and Infectious Diseases 49
Jan 06, 2015: Inovio Pharmaceuticals HIV Immunotherapy Shows Characteristics Considered Vital to Treating HIV 49
Oct 29, 2014: GeoVax Presents HIV Vaccine Clinical Trial Data 50
Jul 30, 2014: GeoVax Awarded Small Business Innovative Research (SBIR) Grant from National Institutes of Health 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53

List of Tables
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Route of Administration, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by GeoVax Labs, Inc., H2 2016 21
Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 22
Pipeline by Johnson & Johnson, H2 2016 23
Dormant Projects, H2 2016 40

List of Figures
Number of Products under Development for, H2 2016 7
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Routes of Administration, H2 2016 17
Number of Products by Stage and Routes of Administration, H2 2016 17
Number of Products by Molecule Types, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 19

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *